Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors.
The article "Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors, by M. Qian, N.-J. Song, published in Eur Rev Med Pharmacol Sci 2018; 22 (13): 4299-4309-DOI: 10.26355/eurrev_201807_15426-PMID: 30024620" has been withdrawn from the authors since the conclusions of the paper had some shortcomings and the authors decided to improve them further. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/15426.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|3 区医学
小类|3 区药学
最新[2025]版：
无
第一作者：
第一作者机构：[1]Department of Dermatology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
推荐引用方式(GB/T 7714)：
Qian M,Song N-J.Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors.[J].European Review For Medical And Pharmacological Sciences.2021,25(10):3642.doi:10.26355/eurrev_202105_25923.
APA：
Qian M&Song N-J.(2021).Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors..European Review For Medical And Pharmacological Sciences,25,(10)
MLA：
Qian M,et al."Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors.".European Review For Medical And Pharmacological Sciences 25..10(2021):3642
